These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

988 related articles for article (PubMed ID: 32006266)

  • 21. Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus.
    Scheen AJ
    Clin Pharmacokinet; 2014 Apr; 53(4):295-304. PubMed ID: 24420910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
    Lupsa BC; Inzucchi SE
    Diabetologia; 2018 Oct; 61(10):2118-2125. PubMed ID: 30132031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus.
    Kashiwagi A; Maegawa H
    J Diabetes Investig; 2017 Jul; 8(4):416-427. PubMed ID: 28178390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan.
    Ito H; Shinozaki M; Nishio S; Abe M
    Expert Opin Pharmacother; 2016 Oct; 17(15):2073-84. PubMed ID: 27592508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function.
    Suijk DLS; van Baar MJB; van Bommel EJM; Iqbal Z; Krebber MM; Vallon V; Touw D; Hoorn EJ; Nieuwdorp M; Kramer MMH; Joles JA; Bjornstad P; van Raalte DH
    Clin J Am Soc Nephrol; 2022 May; 17(5):663-671. PubMed ID: 35322793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes.
    Steen O; Goldenberg RM
    Can J Diabetes; 2017 Oct; 41(5):517-523. PubMed ID: 28942789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis.
    Cai X; Yang W; Gao X; Chen Y; Zhou L; Zhang S; Han X; Ji L
    Obesity (Silver Spring); 2018 Jan; 26(1):70-80. PubMed ID: 29165885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus.
    Said S; Hernandez GT
    Cardiovasc Hematol Agents Med Chem; 2013 Sep; 11(3):203-6. PubMed ID: 24025022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes.
    Woo VC
    Can J Diabetes; 2020 Feb; 44(1):61-67. PubMed ID: 31839265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke.
    Al Hamed FA; Elewa H
    Clin Ther; 2020 Nov; 42(11):e242-e249. PubMed ID: 33008610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    J Pharmacol Sci; 2016 Jul; 131(3):198-208. PubMed ID: 27430987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension.
    Kimura T; Sanada J; Shimoda M; Hirukawa H; Fushimi Y; Nishioka M; Kinoshita T; Okauchi S; Obata A; Kohara K; Tatsumi F; Kamei S; Nakanishi S; Mune T; Kaku K; Kaneto H
    J Diabetes Investig; 2018 Jul; 9(4):875-881. PubMed ID: 29110406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
    Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N
    Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology.
    Tanaka A; Node K
    J Cardiol; 2017 Mar; 69(3):501-507. PubMed ID: 28043708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart.
    Santulli G; Varzideh F; Forzano I; Wilson S; Salemme L; de Donato A; Lombardi A; Rainone A; Nunziata L; Jankauskas SS; Tesorio T; Guerra G; Kansakar U; Mone P
    Hypertension; 2023 Sep; 80(9):1800-1809. PubMed ID: 37403685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of SGLT2 Inhibitors as the Fifth Drug in the Management of Type 2 Diabetes Mellitus in Asian Indians not Controlled with at least 4 Oral Antidiabetic Drugs.
    Panikar V; Joshi SR; Deogaonkar N; Vadgama J; Nasikkar N; Kamat T; Sheikh S; Jain CC; Wagle T
    J Assoc Physicians India; 2018 Dec; 66(12):46-49. PubMed ID: 31315325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.